Evidence map›Paper›PMID 40467630›Full record

ArticleScientific reports2025

Analysis of human factor H-related gene and protein expressed in rheumatoid arthritis synovium identifies a novel mechanism promoting dysregulated complement pathway activation.

Nirmal K Banda, Larry W Moreland, Kevin D Deane, Dmitri Simberg, Robert I Scheinman, Rachel M Frank, Jennifer A Seifert, Accelerating Medicines Partnership (AMP) RA/SLE Network, Rachel Lau, Costantino Pitzalis and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nirmal K BandaDivision of Rheumatology B115, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO, 80045, USA. Nirmal.Banda@cuanschutz.edu.
Larry W MorelandDivision of Rheumatology B115, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO, 80045, USA.
Kevin D DeaneDivision of Rheumatology B115, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO, 80045, USA.
Dmitri SimbergDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Robert I ScheinmanDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Rachel M FrankDepartment of Orthopedics and the Colorado Program for Musculoskeletal Research, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Jennifer A SeifertDivision of Rheumatology B115, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO, 80045, USA.
Accelerating Medicines Partnership (AMP) RA/SLE Network
Rachel LauCentre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Costantino PitzalisCentre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Myles J LewisCentre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
V Michael HolersDivision of Rheumatology B115, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO, 80045, USA.

Funding

Complement in the Pathogenesis of Autoimmune ArthritisR01AR051749 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Vernon Michael Holers · 2004 to 2026
$6.7M
Complement in the Pathogenesis of Autoimmune ArthritisR56AR051749 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2020 to 2020
$342k
National Institute of Health United states AR51749NIAMS NIH HHS R01 AR051749NIAMS NIH HHS R56 AR051749NIH HHS AR51749
6 · The paper itself

Abstract

Factor H (FH) is a negative regulator of the alternative pathway (AP) of complement however, five human factor H-related (FHR) proteins, can also function ex vivo as positive regulators. We compare bulk FH and FHR mRNA expressions in both the human rheumatoid arthritis (RA) synovium and blood cells from the Pathobiology of Early Arthritis Cohort (PEAC) and the Stratification of biological therapies for Rheumatoid Arthritis by Pathobiology (STRAP) Cohort. FH and FHR proteins were detected using multiplexed immunohistochemistry (MIHC) in synovium. In three pathotypes, in the synovium, no differences were found in the expression of FHR mRNA. In the synovium, a significant negative correlation was observed between FH expression and the disease activity score and X-ray joint space narrowing. In RA patients, there was a significant positive correlation between FHR3 mRNA level, anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF). FHR proteins were co-localized in the synovial lining area along with complement C3 while FH was almost undetectable in the synovial lining but abundant in sub-synovial lining areas. We do not know whether FH and FHR proteins are locally generated and deposited in synovium or come from circulation. In sum, due to the absence of FH but the presence of FHRs, the synovial lining might fail to be protected from complement-mediated attack, and FHR3 may play a particularly important pathogenic role.

Indexed as

Arthritis, RheumatoidComplement ActivationComplement Factor HSynovial MembraneAdultAgedFemaleHumansMaleMiddle AgedRheumatoid FactorRNA, MessengerComplement Factor HRheumatoid FactorRNA, Messenger

Identifiers

PMID40467630
PMCPMC12137822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.